Prospective study on Maresin-1 and cytokine levels in medication-naïve adolescents with first-episode major depressive disorder
- PMID: 37009097
- PMCID: PMC10050445
- DOI: 10.3389/fpsyt.2023.1132791
Prospective study on Maresin-1 and cytokine levels in medication-naïve adolescents with first-episode major depressive disorder
Abstract
Background: Inflammation and immune activation may play a role in the pathological mechanism of Major Depressive Disorder (MDD). Evidence from cross-sectional and longitudinal studies of adolescents and adults has shown that MDD is associated with increased plasma pro-inflammatory cytokines (e.g., IL-1β, IL-6). It has been reported that Specialized Pro-resolving Mediators (SPMs) mediate inflammation resolution, and Maresin-1 can activate the process of inflammation and promote inflammation resolution by promoting macrophage phagocytosis. However, no clinical studies have been conducted to evaluate the relationship between the levels of Maresin-1 and cytokine and the severity of MDD symptomatology in adolescents.
Methods: 40 untreated adolescent patients with primary and moderate to severe MDD and 30 healthy participants as the healthy control (HC) group aged between 13 and 18 years old were enrolled. They received clinical and Hamilton Depression Rating Scale (HDRS-17) evaluation and then, blood samples were collected. Patients in the MDD group were re-evaluated for HDRS-17, and blood samples were taken after a six to eight-week fluoxetine treatment.
Results: The adolescent patients with MDD had lower serum levels of Maresin-1 and higher serum levels of interleukin 6 (IL-6) compared with the HC group. Fluoxetine treatment alleviated depressive symptoms in MDD adolescent patients, which was reflected by higher serum levels of Maresin-1 and IL-4 and lower HDRS-17 scores, serum levels of IL-6, and IL-1β. Moreover, the serum level of Maresin-1 was negatively correlated with the depression severity scores on the HDRS-17.
Conclusion: Adolescent patients with primary MDD had lower levels of Maresin-1 and higher levels of IL-6 compared with the HC group, implying that the peripheral level of pro-inflammatory cytokines may be elevated in MDD, resulting in the insufficiency of inflammation resolution. The Maresin-1 and IL-4 levels increased after anti-depressant treatment, whereas IL-6 and IL-1β levels decreased significantly. Moreover, Maresin-1 level negatively correlated with depression severity, suggesting that reduced levels of Maresin-1 promoted the progression of MDD.
Keywords: Maresin-1; adolescent; cytokines; major depressive disorder; medication-naïve.
Copyright © 2023 Qiu, Li, Chen, He, Shi, Zhou, Zheng, Lei, Tang, Yu, Du and Guo.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
The relationship between serum resolvin D1, NLRP3, cytokine levels, and adolescents with first-episode medication-naïve major depressive disorder.BMC Psychiatry. 2024 Apr 16;24(1):285. doi: 10.1186/s12888-024-05724-0. BMC Psychiatry. 2024. PMID: 38627683 Free PMC article. Clinical Trial.
-
[Effect of Sertraline on Serum Cytokine Levels in Adolescents With First-Episode Major Depressive Disorder].Sichuan Da Xue Xue Bao Yi Xue Ban. 2023 Mar;54(2):310-315. doi: 10.12182/20230360204. Sichuan Da Xue Xue Bao Yi Xue Ban. 2023. PMID: 36949691 Free PMC article. Chinese.
-
Prospective study on cytokine levels in medication-naïve adolescents with first-episode major depressive disorder.J Affect Disord. 2020 Apr 1;266:57-62. doi: 10.1016/j.jad.2020.01.125. Epub 2020 Jan 23. J Affect Disord. 2020. PMID: 32056928
-
Changes in peripheral blood compounds following psychopharmacological treatment in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis.Psychol Med. 2021 Mar;51(4):538-549. doi: 10.1017/S0033291721000155. Epub 2021 Mar 3. Psychol Med. 2021. PMID: 33653423 Free PMC article.
-
Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: A systematic review and meta-analysis.Brain Behav Immun. 2019 Jul;79:24-38. doi: 10.1016/j.bbi.2019.02.021. Epub 2019 Feb 21. Brain Behav Immun. 2019. PMID: 30797959
Cited by
-
Is Lipid Metabolism of Value in Cancer Research and Treatment? Part II: Role of Specialized Pro-Resolving Mediators in Inflammation, Infections, and Cancer.Metabolites. 2024 May 29;14(6):314. doi: 10.3390/metabo14060314. Metabolites. 2024. PMID: 38921449 Free PMC article. Review.
-
Biomarkers associated with treatment outcome in young people with depression: A systematic review.Neurosci Appl. 2024 Jul 2;3:104082. doi: 10.1016/j.nsa.2024.104082. eCollection 2024. Neurosci Appl. 2024. PMID: 40656097 Free PMC article. Review.
-
Fluoxetine attenuates stress-induced depression-like behavior due to decrease in pro-inflammatory cytokines in male rats.Sci Prog. 2024 Jan-Mar;107(1):368504241234786. doi: 10.1177/00368504241234786. Sci Prog. 2024. PMID: 38490226 Free PMC article.
-
Association of inflammation cytokines with cognitive function in first-episode major depressive disorder.Front Psychiatry. 2025 Jan 22;15:1473418. doi: 10.3389/fpsyt.2024.1473418. eCollection 2024. Front Psychiatry. 2025. PMID: 39911552 Free PMC article.
References
-
- GBD 2016 Disease and injury incidence and prevalence . Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. (2017) 390:1211–59. doi: 10.1016/S0140-6736(17)32154-2, PMID: - DOI - PMC - PubMed
-
- Avenevoli S, Baio J, Bitsko RH, Blumberg SJ, Brody DJ, Crosby A, et al. . Mental health surveillance among children—United States, 2005–2011. (2013). MMWR supplements, 62:1–35. - PubMed
LinkOut - more resources
Full Text Sources